参考文献

［1］Diamond EL，Dagna L，Hyman DM，et al. Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood，2014，124：483-492.

［2］Arnaud L，Gorochov G，Charlotte F，et al. Systemic perturbation of cytokine and chemokine networks in Erdheim-Chester disease：a singlecenter series of 37 patients. Blood，2011，117：2783-2790.

［3］Emile JF，Abla O，Fraitag S，et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood，2016，127：2672-2681.

［4］Arnaud L，Malek Z，Archambaud F，et al. 18F-fluorodeoxyglucosepositron emission tomography scanning is more useful in followup than in the initial assessment of patients with Erdheim-Chester disease.Arthritis Rheum，2009，60：3128-3138.

［5］Cao XX，Sun J，Li J，et al. Evaluation of clinicopathologic characteristics and the BRAF V600E mutation in Erdheim-Chester disease among Chinese adults. Ann Hematol，2016，95：745-750.